Novavax is a part of the FDA’s COVID-19 booster debate, however its vaccine nonetheless hasn’t been licensed
Novavax’s NVAX, +1.55% COVID-19 vaccine candidate performed a front-and-center function throughout this week’s debate about how greatest to replace the COVID-19 boosters to raised defend towards omicron. The catch? The firm’s major collection of pictures are nonetheless being reviewed by U.S. regulators. Novavax’s recombinant protein COVID-19 vaccine candidate has been considered as a attainable different … Read more